Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties.
暂无分享,去创建一个
Morteza Mahmoudi | Giulio Caracciolo | Francesca Baldelli Bombelli | Arafeh Bigdeli | G. Caracciolo | M. Mahmoudi | M. Hormozi-Nezhad | F. Baldelli Bombelli | D. Pozzi | S. Palchetti | A. Bigdeli | Daniela Pozzi | Sara Palchetti | Mohammad Reza Hormozi-Nezhad
[1] Andrew Emili,et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. , 2014, ACS nano.
[2] T. Puzyn,et al. Toward the development of "nano-QSARs": advances and challenges. , 2009, Small.
[3] Morteza Mahmoudi,et al. Personalized protein coronas: a "key" factor at the nanobiointerface. , 2014, Biomaterials science.
[4] Raimo Hartmann,et al. Temperature: the "ignored" factor at the NanoBio interface. , 2013, ACS nano.
[5] Rasmus Bro,et al. Variable selection in regression—a tutorial , 2010 .
[6] Giulio Caracciolo,et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. , 2014, Nanoscale.
[7] P. Gemperline. Practical Guide To Chemometrics , 2006 .
[8] P. Cullis,et al. Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.
[9] Stefan Tenzer,et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.
[10] Giulio Caracciolo,et al. Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. , 2011, Langmuir : the ACS journal of surfaces and colloids.
[11] David J. C. MacKay,et al. A Practical Bayesian Framework for Backpropagation Networks , 1992, Neural Computation.
[12] Giulio Caracciolo,et al. Do plasma proteins distinguish between liposomes of varying charge density? , 2012, Journal of proteomics.
[13] Gerard W. Doorley,et al. Cellular binding of nanoparticles in the presence of serum proteins. , 2011, Chemical communications.
[14] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[15] S. Provencher. A constrained regularization method for inverting data represented by linear algebraic or integral equations , 1982 .
[16] Giulio Caracciolo,et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.
[17] Iseult Lynch,et al. Protein-nanoparticle interactions: What does the cell see? , 2009, Nature nanotechnology.
[18] Warren C. W. Chan,et al. Understanding and Controlling the Interaction of Nanomaterials with Proteins in a Physiological Environment , 2012 .
[19] Paola Gramatica,et al. The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .
[20] Kevin Braeckmans,et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. , 2013, ACS nano.
[21] G. Caracciolo,et al. The liposome-protein corona in mice and humans and its implications for in vivo delivery. , 2014, Journal of materials chemistry. B.
[22] W. Chan,et al. Prediction of nanoparticles-cell association based on corona proteins and physicochemical properties. , 2015, Nanoscale.
[23] Kostas Kostarelos,et al. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. , 2011, Accounts of chemical research.
[24] G. Caracciolo,et al. The biomolecular corona of nanoparticles in circulating biological media. , 2015, Nanoscale.
[25] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[26] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[27] Martin Lundqvist,et al. Nanoparticles: Tracking protein corona over time. , 2013, Nature nanotechnology.
[28] Paola Gramatica,et al. Principles of QSAR models validation: internal and external , 2007 .
[29] Giulio Caracciolo,et al. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[30] Iseult Lynch,et al. What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.
[31] Ka-Ho Leung,et al. Antagonizing STAT3 dimerization with a rhodium(III) complex. , 2014, Angewandte Chemie.
[32] Kenneth A. Dawson,et al. Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.